Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Study Design of TAK-341-2001: A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-341 in Subjects With Multiple System Atrophy
Neuromuscular and Clinical Neurophysiology (EMG)
P9 - Poster Session 9 (5:30 PM-6:30 PM)
4-003

MSA is a rapidly progressing and fatal neurological disorder, with no treatments that can slow its progression. TAK-341 (MEDI1341) is a monoclonal antibody that binds to the C-terminal region of human alpha-synuclein. In a mouse model, TAK-341 attenuated cell-to-cell spreading of alpha-synuclein pathology in the brain.  Single ascending dose (NCT03272165) and multiple ascending dose (NCT04449484) studies in healthy participants and participants with Parkinson disease, respectively, have recently completed and support continued development of TAK-341.

To describe the design of a clinical trial that will evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenously administered TAK-341 in participants with multiple system atrophy (MSA).

This randomized, double-blind, placebo-controlled, Ph2 study (NCT05526391) will enroll approximately 138 participants globally who are ≥40 years of age, with probable or possible MSA according to modified Gilman 2008 criteria. Participants’ onset of MSA symptoms must have occurred ≤4 years before screening as demonstrated by MSA symptoms measured with the Unified MSA Rating Scale (UMSARS). 

Participants will receive 13 intravenous infusions of either TAK-341 or placebo, approximately every 4 weeks. The study comprises a ≤42-day screening period, a 52-week double-blind treatment period, and a follow-up safety visit.

The study’s primary objective is to evaluate the efficacy of TAK-341 versus placebo, as measured by the change from baseline after 52 weeks on a modified UMSARS Part I. Secondary objectives are to evaluate the efficacy of TAK-341 versus placebo, as measured by change from baseline after 52 weeks on the following: UMSARS Part I, Part II, and total scores, an 11-item selection of UMSARS Part I and II items, CGI-S, SCOPA-AUT, and overall survival. Secondary objectives also include evaluation of pharmacokinetic parameters.  Safety endpoints will also be evaluated.
Recruiting
Trial results will yield insight into the role of alpha-synuclein in MSA disease progression, and further inform TAK-341’s risk-benefit profile.
Authors/Disclosures
Jaya Padmanabhan
PRESENTER
Jaya Padmanabhan has received personal compensation for serving as an employee of Takeda Pharmaceuticals. Jaya Padmanabhan has stock in Takeda Pharmaceuticals.
Elena Ratti, MD (Takeda) Dr. Ratti has received personal compensation for serving as an employee of Takeda. Dr. Ratti has received personal compensation for serving as an employee of Biogen. Dr. Ratti has stock in Takeda. Dr. Ratti has stock in Biogen.
Polyna Khudyakov, PhD (Sage Therapeutics) Dr. Khudyakov has nothing to disclose.
Wei Yin Wei Yin has received personal compensation for serving as an employee of Takeda. Wei Yin has stock in Takeda.
Stephen Zicha, PhD (Takeda Pharmaceutical Company Ltd) Mr. Zicha has stock in Takeda Pharmaceutical Company Ltd.
Olga Golonzhka, PhD (Takeda) Dr. Golonzhka has nothing to disclose.
Tairmae Kangarloo No disclosure on file
Brian Harel, PhD Brian Harel has received personal compensation for serving as an employee of Takeda. An immediate family member of Brian Harel has received personal compensation for serving as an employee of Astra Zeneca. Brian Harel has stock in Takeda, Merck, Day One Biopharmaceuticals. An immediate family member of Brian Harel has stock in Eli Lilly, Pfizer, Astra Zeneca. Brian Harel has stock in Cogstate.
Nancy Goodman (Takeda Pharmaceuticals) Mrs. Goodman has nothing to disclose.
Emmanuelle Magueur, Other (Takeda Pharmaceuticals) Mrs. Magueur has received personal compensation for serving as an employee of Takeda . Mrs. Magueur has stock in Takeda Pharmaceuticals.
Craig Shering, Other (AstraZeneca) Dr. Shering has received personal compensation for serving as an employee of AstraZeneca. An immediate family member of Dr. Shering has received personal compensation for serving as an employee of eResearch Technology Inc. Dr. Shering has stock in AstraZeneca. Dr. Shering has received intellectual property interests from a discovery or technology relating to health care.
Thor Ostenfeld, MBBS,PhD (AstraZeneca) Dr. Ostenfeld has received personal compensation for serving as an employee of AstraZeneca. Dr. Ostenfeld has stock in AstraZeneca. Dr. Ostenfeld has received intellectual property interests from a discovery or technology relating to health care.
Antonio Laurenza, MD, FAAN (Takeda Pharmacautcals) Dr. Laurenza has received personal compensation for serving as an employee of Takeda. Dr. Laurenza has stock in Takeda.
Arthur Simen Arthur Simen has received personal compensation for serving as an employee of Takeda.